MEDICAL SCIENCES Correction for “Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy,” by Jachinta E. Rooney, Praveen B. Gurpur, and Dean J. Burkin, which appeared in issue 19, May 12, 2009, of Proc Natl Acad Sci USA (106:7991–7996; first published April 28, 2009; 10.1073/pnas.0811599106).
The authors note that in preparing Fig. 3A, an image from Fig. 6A was inadvertently inserted. This error does not affect the conclusions of the article. The corrected figure and its legend appear below.
Fig. 3.
Intramuscular injection of laminin-111 prevents muscle disease in mdx mice. (A) Immunofluorescence of the TA muscles of control and laminin-111-treated mice confirms the absence of dystrophin in mdx muscle treated with LAM-111 or PBS. Laminin-111 was not present in wild-type or PBS-injected mdx muscle, but it was detected in the extracellular matrix of laminin-111-injected mdx muscle. (Scale bar: 10 μm.) (B) EBD uptake reveals that mdx muscle injected with laminin-111 exhibits reduced EBD uptake compared with control. (Scale bar: 10 μm.) H&E staining reveals that mdx muscle treated with laminin-111 contains few muscle fibers with centrally located nuclei and mononuclear cell infiltrate compared with control. (C) Quantitation reveals wild-type and mdx muscle treated with laminin-111 contained significantly fewer EBD-positive fibers and myofibers with centrally located nuclei compared with control. *, P < 0.05; **, P < 0.001; n = 5 mice per group.